Lingshi Tan, Ph.D.

Chairman & Chief Executive Officer

As global Chairman and CEO, Dr. Lingshi Tan sets and leads the company’s strategy while overseeing the leadership team to ensure Caidya helps bring life-changing therapies to our global community.

Lingshi founded dMed in Shanghai in 2016 and took the company global via a merger with Clinipace in 2021. Prior to founding dMed, he was Pfizer’s VP of Worldwide Development Operations and Chairman and GM of Pfizer (China) Research & Development Co., Ltd. (CRDC). He was assigned from New York to Shanghai to establish the CRDC in 2005. Under Lingshi’s Leadership, the CRDC grew to an organization of more than 1,000 professionals and became an integral part of Pfizer’s global R&D network, focusing on clinical development, safety, regulatory, and medical functions.

Lingshi earned his PhD in Biostatistics from the University of Pittsburgh, US. He was a member of the Drug Information Association (DIA) Global Board of Directors from 2016 to 2022, including serving as Chair, and is now Chair of Fellows of DIA.

Global reach, local knowledge

Speak to one of our experts

Access the right people when and where you need them with personalized clinical services tailored to you and your trial.

Schedule a 15 minute call
Leading a new way

The latest from Caidya

Explore our news and updates as we liberate the clinical research process.

News

10/03/22

dMed | Clinipace announce corporate name change to Caidya

SHANGHAI and MORRISVILLE, N.C., October 3, 2022 – dMed | Clinipace, ...

News

04/28/21

CROs dMed and Clinipace merge to accelerate customer success

SHANGHAI, CHINA and MORRISVILLE, NORTH CAROLINA, USA, April 28, 2021 – ...